156 related articles for article (PubMed ID: 23927624)
1. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
Harja E; Lord J; Skyler JS
Diabetes Technol Ther; 2013 Aug; 15(8):609-18. PubMed ID: 23927624
[TBL] [Abstract][Full Text] [Related]
2. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.
Lando HM; Alattar M; Dua AP
Endocr Pract; 2012; 18(4):472-7. PubMed ID: 22440997
[TBL] [Abstract][Full Text] [Related]
3. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Elashoff M; Matveyenko AV; Gier B; Elashoff R; Butler PC
Gastroenterology; 2011 Jul; 141(1):150-6. PubMed ID: 21334333
[TBL] [Abstract][Full Text] [Related]
4. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
Iyer SN; Drake AJ; West RL; Mendez CE; Tanenberg RJ
Endocr Pract; 2012; 18(1):e10-3. PubMed ID: 22068258
[TBL] [Abstract][Full Text] [Related]
5. Pancreatitis associated with incretin-based therapies.
Iyer SN; Tanenberg RJ; Mendez CE; West RL; Drake AJ
Diabetes Care; 2013 Apr; 36(4):e49. PubMed ID: 23520376
[No Abstract] [Full Text] [Related]
6. [Incretin related agents for treatment of diabetes mellitus].
Miyagawa J; Miuchi M; Nanba M
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544
[No Abstract] [Full Text] [Related]
7. Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S20-7. PubMed ID: 20824236
[TBL] [Abstract][Full Text] [Related]
8. GLP-1-based therapies: the dilemma of uncertainty.
Spranger J; Gundert-Remy U; Stammschulte T
Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985
[No Abstract] [Full Text] [Related]
9. [Therapeutic use and adverse events of incretin-related drugs].
Ishikawa M; Yamada Y
Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
[No Abstract] [Full Text] [Related]
10. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.
Dore DD; Seeger JD; Arnold Chan K
Curr Med Res Opin; 2009 Apr; 25(4):1019-27. PubMed ID: 19278373
[TBL] [Abstract][Full Text] [Related]
11. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
12. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.
Ryder RE
Diabet Med; 2013 Oct; 30(10):1148-55. PubMed ID: 24073725
[TBL] [Abstract][Full Text] [Related]
13. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
Xu L; Spinas GA; Niessen M
Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
[No Abstract] [Full Text] [Related]
14. One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
Aston-Mourney K; Subramanian SL; Zraika S; Samarasekera T; Meier DT; Goldstein LC; Hull RL
Am J Physiol Endocrinol Metab; 2013 Aug; 305(4):E475-84. PubMed ID: 23736544
[TBL] [Abstract][Full Text] [Related]
15. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
Butler AE; Campbell-Thompson M; Gurlo T; Dawson DW; Atkinson M; Butler PC
Diabetes; 2013 Jul; 62(7):2595-604. PubMed ID: 23524641
[TBL] [Abstract][Full Text] [Related]
16. [New drugs; exenatide and sitagliptin].
van Bronswijk H; Dubois EA; Pijl H; Cohen AF
Ned Tijdschr Geneeskd; 2008 Apr; 152(15):876-9. PubMed ID: 18512528
[TBL] [Abstract][Full Text] [Related]
17. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
Grunberger G
J Diabetes; 2013 Sep; 5(3):241-53. PubMed ID: 23489968
[TBL] [Abstract][Full Text] [Related]
18. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
19. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
[TBL] [Abstract][Full Text] [Related]
20. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]